Intrinsic breast cancer subtypes defined by estrogen receptor signalling

• Verfasst von: Braun, Lisa [VerfasserIn]
• Verfasst von: Mietzsch, Friederike [VerfasserIn]
• Verfasst von: Seibold, Petra Beate [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Verfasst von: Schirmacher, Peter [VerfasserIn]
• Verfasst von: Chang-Claude, Jenny [VerfasserIn]
• Verfasst von: Sinn, Peter [VerfasserIn]
• Verfasst von: Aulmann, Sebastian [VerfasserIn]
• Titel: Intrinsic breast cancer subtypes defined by estrogen receptor signalling
• Titelzusatz: prognostic relevance of progesterone receptor loss
• Verf.angabe: Lisa Braun, Friederike Mietzsch, Petra Seibold, Andreas Schneeweiss, Peter Schirmacher, Jenny Chang-Claude, Hans Peter Sinn and Sebastian Aulmann
• E-Jahr: 2013
• Jahr: 5 April 2013
• Umfang: 11 S.
• Fussnoten: Gesehen am 03.12.2020
• Titel Quelle: Enthalten in: Modern pathology
• Ort Quelle: London : Nature Publishing Group, 1988
• Jahr Quelle: 2013
• Band/Heft Quelle: 26(2013), 9, Seite 1161-1171
• ISSN Quelle: 1530-0285
• DOI: doi:10.1038/modpathol.2013.60
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1741963214

Abstract

The majority of luminal type breast carcinomas are slowly growing tumors with an overall favorable prognosis. However, a proportion of cases (luminal B tumors) are characterized by coactivation of growth factor receptors or non-canonical ER signaling and a poorer clinical outcome. The aim of our study was to evaluate whether the expression of proteins that are part of the ER signaling network may be used to distinguish low-risk from high-risk luminal tumors. Unsupervised hierarchical clustering of a set of proteins either involved in estrogen receptor signaling or associated with resistance to endocrine therapy was performed in a series of 443 postmenopausal breast carcinomas. Using this approach, we were able to reproduce the established classification with two distinct groups of luminal (estrogen receptor positive) tumors, one group of HER2-associated tumors and a group of triple-negative tumors. However, neither proliferation nor the expression of one or more of the ER-co-factors or resistance-associated factors, but PR-expression was identified as the most important stratifier distinguishing between the two luminal groups. In fact, not only the four identified clusters were shown to be significantly associated with patient outcome, PR-expression alone or in combination with Ki-67-stains stratified ER-positive tumors into a low-risk and a high-risk group. Our data indicate that defining luminal B tumors by the presence of high-risk criteria (loss of PR-expression or increased proliferation) provides a robust and highly significant stratification of ER-positive breast carcinomas into luminal A and B.